144 related articles for article (PubMed ID: 35391614)
1. NRAS
Boscolo E; Pastura P; Schrenk S; Goines J; Kang R; Pillis D; Malik P; Le Cras TD
Angiogenesis; 2022 Aug; 25(3):331-342. PubMed ID: 35391614
[TBL] [Abstract][Full Text] [Related]
2. NRAS
Pastura P; McDaniel CG; Alharbi S; Fox D; Coleman B; Malik P; Adams DM; Le Cras TD
Pediatr Blood Cancer; 2024 Jul; 71(7):e31032. PubMed ID: 38711167
[TBL] [Abstract][Full Text] [Related]
3. Treatment of severe Kaposiform lymphangiomatosis positive for NRAS mutation by MEK inhibition.
Chowers G; Abebe-Campino G; Golan H; Vivante A; Greenberger S; Soudack M; Barkai G; Fox-Fisher I; Li D; March M; Battig MR; Hakonarson H; Adams D; Dori Y; Dagan A
Pediatr Res; 2023 Dec; 94(6):1911-1915. PubMed ID: 35246606
[TBL] [Abstract][Full Text] [Related]
4. Changes in cell morphology and function induced by the NRAS Q61R mutation in lymphatic endothelial cells.
Yasue S; Ozeki M; Nozawa A; Endo S; Ohnishi H
PLoS One; 2024; 19(5):e0289187. PubMed ID: 38809881
[TBL] [Abstract][Full Text] [Related]
5. Lymphatic endothelial cell-specific NRAS p.Q61R mutant embryos show abnormal lymphatic vessel morphogenesis.
Nozawa A; Abe T; Niihori T; Ozeki M; Aoki Y; Ohnishi H
Hum Mol Genet; 2024 May; ():. PubMed ID: 38743908
[TBL] [Abstract][Full Text] [Related]
6. SP174, NRAS Q61R Mutant-Specific Antibody, Cross-Reacts With KRAS Q61R Mutant Protein in Colorectal Carcinoma.
Lasota J; Kowalik A; Felisiak-Golabek A; Inaguma S; Wang ZF; Pięciak L; Zięba S; Pęksa R; Kopczynski J; Okoń K; Waloszczyk P; Gozdz S; Biernat W; Miettinen M
Arch Pathol Lab Med; 2017 Apr; 141(4):564-568. PubMed ID: 28353383
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemistry as a potential tool for routine detection of the NRAS Q61R mutation in patients with metastatic melanoma.
Ilie M; Long-Mira E; Funck-Brentano E; Lassalle S; Butori C; Lespinet-Fabre V; Bordone O; Gay A; Zahaf K; Poissonnet G; Lacour JP; Bahadoran P; Ballotti R; Gros A; Dutriaux C; Saiag P; Merlio JP; Vergier B; Emile JF; Hofman V; Hofman P
J Am Acad Dermatol; 2015 May; 72(5):786-93. PubMed ID: 25659223
[TBL] [Abstract][Full Text] [Related]
8. A somatic activating NRAS variant associated with kaposiform lymphangiomatosis.
Barclay SF; Inman KW; Luks VL; McIntyre JB; Al-Ibraheemi A; Church AJ; Perez-Atayde AR; Mangray S; Jeng M; Kreimer SR; Walker L; Fishman SJ; Alomari AI; Chaudry G; Trenor Iii CC; Adams D; Kozakewich HPW; Kurek KC
Genet Med; 2019 Jul; 21(7):1517-1524. PubMed ID: 30542204
[TBL] [Abstract][Full Text] [Related]
9. BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting.
Kakavand H; Walker E; Lum T; Wilmott JS; Selinger CI; Smith E; Saw RP; Yu B; Cooper WA; Long GV; O'Toole SA; Scolyer RA
Histopathology; 2016 Oct; 69(4):680-6. PubMed ID: 27151331
[TBL] [Abstract][Full Text] [Related]
10. SP174 Antibody Lacks Specificity for NRAS Q61R and Cross-Reacts With HRAS and KRAS Q61R Mutant Proteins in Malignant Melanoma.
Felisiak-Goląbek A; Inaguma S; Kowalik A; Wasąg B; Wang ZF; Zięba S; Pięciak L; Ryś J; Kopczynski J; Sarlomo-Rikala M; Góźdź S; Lasota J; Miettinen M
Appl Immunohistochem Mol Morphol; 2018 Jan; 26(1):40-45. PubMed ID: 29206715
[TBL] [Abstract][Full Text] [Related]
11. NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.
Uguen A; Talagas M; Costa S; Samaison L; Paule L; Alavi Z; De Braekeleer M; Le Marechal C; Marcorelles P
Diagn Pathol; 2015 Jul; 10():121. PubMed ID: 26204954
[TBL] [Abstract][Full Text] [Related]
12. Detection of NRAS mutation in cell-free DNA biological fluids from patients with kaposiform lymphangiomatosis.
Ozeki M; Aoki Y; Nozawa A; Yasue S; Endo S; Hori Y; Matsuoka K; Niihori T; Funayama R; Shirota M; Nakayama K; Fukao T
Orphanet J Rare Dis; 2019 Sep; 14(1):215. PubMed ID: 31511039
[TBL] [Abstract][Full Text] [Related]
13. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.
Posch C; Moslehi H; Feeney L; Green GA; Ebaee A; Feichtenschlager V; Chong K; Peng L; Dimon MT; Phillips T; Daud AI; McCalmont TH; LeBoit PE; Ortiz-Urda S
Proc Natl Acad Sci U S A; 2013 Mar; 110(10):4015-20. PubMed ID: 23431193
[TBL] [Abstract][Full Text] [Related]
14. Somatic NRAS mutation in patient with generalized lymphatic anomaly.
Manevitz-Mendelson E; Leichner GS; Barel O; Davidi-Avrahami I; Ziv-Strasser L; Eyal E; Pessach I; Rimon U; Barzilai A; Hirshberg A; Chechekes K; Amariglio N; Rechavi G; Yaniv K; Greenberger S
Angiogenesis; 2018 May; 21(2):287-298. PubMed ID: 29397482
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical detection of NRAS(Q61R) protein in follicular-patterned thyroid tumors.
Oishi N; Kondo T; Vuong HG; Nakazawa T; Mochizuki K; Kasai K; Inoue T; Tahara I; Hirokawa M; Miyauchi A; Katoh R
Hum Pathol; 2016 Jul; 53():51-7. PubMed ID: 26980032
[TBL] [Abstract][Full Text] [Related]
16. Characterization of kaposiform lymphangiomatosis tissue-derived cells.
Nozawa A; Ozeki M; Yasue S; Endo S; Noguchi K; Kanayama T; Tomita H; Aoki Y; Ohnishi H
Pediatr Blood Cancer; 2021 Oct; 68(10):e29086. PubMed ID: 33913609
[TBL] [Abstract][Full Text] [Related]
17. NRASQ61R immunohistochemistry detects both NRASQ61R and KRASQ61R mutations in colorectal cancer.
Jhuang JY; Yuan CT; Lin YL; Cheng ML; Liau JY; Tsai JH
Pathology; 2017 Jun; 49(4):387-390. PubMed ID: 28433252
[TBL] [Abstract][Full Text] [Related]
18. NRAS Q61R immunohistochemical staining in thyroid pathology: sensitivity, specificity and utility.
Saliba M; Katabi N; Dogan S; Xu B; Ghossein RA
Histopathology; 2021 Oct; 79(4):650-660. PubMed ID: 33960437
[TBL] [Abstract][Full Text] [Related]
19. GAB2 induces tumor angiogenesis in NRAS-driven melanoma.
Yang Y; Wu J; Demir A; Castillo-Martin M; Melamed RD; Zhang G; Fukunaga-Kanabis M; Perez-Lorenzo R; Zheng B; Silvers DN; Brunner G; Wang S; Rabadan R; Cordon-Cardo C; Celebi JT
Oncogene; 2013 Aug; 32(31):3627-37. PubMed ID: 22926523
[TBL] [Abstract][Full Text] [Related]
20. Efficient Suppression of NRAS-Driven Melanoma by Co-Inhibition of ERK1/2 and ERK5 MAPK Pathways.
Adam C; Fusi L; Weiss N; Goller SG; Meder K; Frings VG; Kneitz H; Goebeler M; Houben R; Schrama D; Schmidt M
J Invest Dermatol; 2020 Dec; 140(12):2455-2465.e10. PubMed ID: 32376279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
